Belgian Immune System Drugmaker AgomAb Files for US IPO
AgomAb Therapeutics NV filed for a initial public offering in the US to help fund trials of its drugs to treat immune and inflammation diseases.
By Anthony Hughes ยท Bloomberg
AgomAb Therapeutics NV filed for a initial public offering in the US to help fund trials of its drugs to treat immune and inflammation diseases.